Prevention for WomenResources on HIV Prevention for U.S. Women
Welcome! This page contains resources relevant to HIV prevention for U.S. women. The resources have been selected by HIVE in collaboration with many HIV prevention advocates nationwide.
To view more resources specifically geared towards trans women, please visit pleaseprepme.org/trans.
New resources will be added periodically. Have suggestions for resources? Let us know! Email Yamini: email@example.com.
HIV is more preventable than ever. You may already know about HIV prevention options such as male (external) and female (internal) condoms, screening and treating sexually transmitted infections, and regular HIV testing—but let’s talk about a few more: PrEP, PEP, and TasP/U=U.
➔ TasP, or treatment as prevention, is when a person living with HIV takes medications to keep the virus at very low levels (called undetectable viral load). Many large studies show that people who take their HIV medicines daily as prescribed and maintain an undetectable viral load have effectively no risk of passing HIV through sex. This concept is also known as U=U, short for “undetectable = untransmittable.”
➔ PrEP, or pre-exposure prophylaxis, is a daily pill to help keep you HIV-negative. When taken as prescribed, PrEP is highly effective. PrEP is safe and generally well tolerated. Most insurance plans (public and private) cover PrEP.
➔ PEP, or post-exposure prophylaxis, is a combination of medications you can take after a possible exposure to HIV. PEP is most effective the sooner it’s started, and must be started within 72 hours of the exposure. PEP is taken daily for 28–30 days
These strategies work for women, men, people of trans experience, people of all sexual orientations and gender identities, youth, and people who inject drugs.
You can use these HIV-prevention strategies alone or in combination to reduce your risk of getting HIV and take charge of your sexual health!
Check out this video Q&A with Dr. Brittany Chambers & Dr. Judy Auerbach to learn more:
HIV and Women
Learn More About HIV and Sexual Health:
- HIV and Women by AIDSinfo/National Library of Medicine
- Black Women & HIV (download/printable brochure) by Black AIDS Institute
- HIV: The Basics (webpage) by The Well Project
- #AskTheHIVDoc (video series) on Women & HIV by Greater Than AIDS
- Why Race Matters: Women & HIV by The Well Project
- 52 Questions: HIV & Sexual Health FAQ (webpage) by HIVE
Recursos en Espanol
Treatment as Prevention and U=U
More about TasP & U=U:
- More on Treatment as Prevention and ‘Undetectable = Untransmittable’ (webpage) by Prevention Access Campaign
- Undetectable = Untransmittable: Building Hope and Ending HIV Stigma (webpage) by The Well Project
- Undetectable = Untransmittable (U=U) for You! By PleasePrEPMe.org
- U=U: What HIV Providers Should Know by Roger Pebody at TheBodyPRO
- Treatment as Prevention for HIV (webpage) by AVERT
Recursos en Espanol
- Indetectable es igual a intransmisible: infundir esperanza y eliminar el estigma de The Well Project
- Indetectable = Intransmisible (I=I) ¡Para usted! de PleasePrEPMe.org
- I=I para Defensores de PleasePrEPMe.org
Advocacy & Training:
- U=U Advocates Page by PleasePrEPMe.org
PrEP (pre-exposure prophylaxis)
Learn More About PrEP:
- Is PrEP Right for Me? (download/printable brochure) by HIVE
- Black Women & PrEP (download/printable brochure) by Black AIDS Institute
- What is PrEP? (webpage) by WhatIsPrEP.org
- Preventing HIV During Pregnancy/Breastfeeding: Using PrEP and/or PEP (download/printable brochure) by HIVE
- A New Option for Women for Safer Loving (download/printable brochure) by Project Inform
- #AskTheHIVDoc Women & PrEP by Greater Than AIDS
- #20DaysToStart: Enhancing Women’s Health, Preventing HIV with a Daily Pill (videos) by Project Inform
- PrEP for Women Fact Sheets (webpage) by The Well Project
- PleasePrEPMe.org/Women (webpage) by PleasePrEPMe.org
- PrEP for Sex (webpage) by New York State Department of Public Health
Advocacy & Training:
- Black Women & PrEP Toolkit by the Black AIDS Institute
- US Women & PrEP Working Group – A national advocacy coalition of women’s health advocates, health care providers and researchers.
- Black AIDS Institute ‘Heard About PrEP?’ slide set for community advocates
- Facebook Group: PrEP Facts: Women’s Sexuality & HIV Prevention
- HIVE’s Resources for PrEP Implementation
- HIVE ::Hangouts with HIVE::
- PrEP Watch: A Clearinghouse for PrEP Information
- PrEP Access Advocates: Listserv of PrEP Advocates from around the U.S. To join, email firstname.lastname@example.org
- Resources for Learning more about PrEP by AVAC & PrEPWatch
- Los Angeles PAETC: PrEP Provider Toolkit
- CDC: US PrEP Clinical Practice Guidelines
- PEP & PrEP consultation from Clinician Consultation Center
- SEICUS: PrEP Toolkit for Youth-Serving Primary Care Providers
- The Well Project: PrEP in Practice: Considerations for HIV Prevention Among Women of Color
- HIVE: Integrating PrEP for HIV Prevention into Women’s Health Care
- HIVE: PrEP Provider Pocket Card
- HIVE: Resources for PrEP Implementation
- HIVE: Family Planning Provider PrEP Toolkit
- PrEPWatch: Oral PrEP Training Materials
- PrEPWatch: PrEP Demonstration Project Tools gallery (guides, questionnaires, interview guides, screening tool).
Recursos en Espanol
- Folleto informativo Sobre PrEP de Project Inform: Una nueva opción para que las mujeres amen de manera más segura
- ¿Es la PrEP adecuada para mi? De HIVE
- Mujeres, PrEP y salud sexual de Project Inform
- PrEP Para Mujeres de The Well Project
Find a Provider
PEP (post-exposure prophylaxis)
Learn More About PEP:
- More on Post-Exposure Prophylaxis (webpage) by PleasePrEPMe.org
- Information on Post-Exposure Prophylaxis (webpage) by the Centers for Disease Control
Preventing HIV During Pregnancy/Breastfeeding: Using PrEP and/or PEP (download/printable brochure) by HIVE
Social Media/Community Building
- Facebook Group: PrEP Facts: Women’s Sexuality & HIV Prevention
- HIVE blog: Share Your Story Campaign
In the Media
- The Body: Celebrating HIV Prevention Choices for Women and Receptive Sex Partners of All Genders by Anna Forbes
- Poz: There’s Never Been a Better Time to Get Pregnant If One of You Has HIV by Ben Ryan
- Beta Blog: Straight Women, Here’s What You (and Everyone) Needs to know About PEP (and PrEP by Emily Land
- Huffington Post: Trusting Women, Shared Decision-Making & The Possibility Of PrEP by Shannon Weber & Dr. Dominika Seidman
- Huffington Post: PrEP For Her: Bringing Women Into The HIV Prevention Conversation by Mehroz Baig
- Huffington Post: Uptake of PrEP Among U.S. Women: Knowledge Is Power by Shannon Weber, Anna Forbes & the U.S. Women & PrEP Working group
- Women’s Health Mag: There’s a Drug That Prevents HIV—So Why Don’t More Women Know About It? By Kristina Marusic
- Huffington Post: Making PrEP Possible for Women by Shannon Weber, Jessica Terlikowski & Dr. Dominika Seidman
- Black Lives Matter: What’s PrEP Got to Do with It? by the Black AIDS Institute
For more, visit HIVE in the media: https://hiveonline.org/hive-in-media/
This is a selected collection of research relevant to HIV prevention for U.S. women. It includes citations on condoms, pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and treatment as prevention (TasP/U=U).
The following questions helped narrow the parameters:
– Does this reference move forward HIV prevention implementation?
– Are the findings new or novel?
– Are the conclusions relevant to HIV-negative U.S. women?
– Will the findings be relevant a year from now?
– Is the publication well written and easy to understand?
– Is the data helpful for HIV prevention implementers?
Included are papers published since 2014 and conference abstracts from HIV & Women Conference, Conference on Retroviruses and Opportunistic Infections (CROI), and the IAPAC Adherence Conference in 2017 and 2018.
Treatment as Prevention, Viral Supression, U=U
Conception, Pregnancy & Breastfeeding
Effects of Antiretroviral Therapy to Prevent HIV Transmission to Women in Couples Attempting Conception When the Man Has HIV Infection – United States, 2017. Brooks JT, Kawwass JF, Smith DK, Kissin DM, Lampe M, Haddad LB, Boulet SL, Jamieson DJ. (2017)
Missed Opportunities for Prevention of Mother-to-Child Transmission of Human Immunodeficiency Virus. Scott GB, Brogly SB, Muenz D, Stek AM, Read JS; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1025 Study Team. (2017)
Perinatal Antiretroviral Exposure and Prevented Mother-to-child HIV Infections in the Era of Antiretroviral Prophylaxis in the United States, 1994-2010. Little KM, Taylor AW, Borkowf CB, Mendoza MC, Lampe MA, Weidle PJ, Nesheim SR. (2017)
Pregnant and breastfeeding women: A priority population for HIV viral load monitoring. Myer L, Essajee S, Broyles LN, Watts DH, Lesosky M, El-Sadr WM, Abrams EJ. (2017)
Reproductive health counseling delivered to women living with HIV in the United States. Gokhale RH, Bradley H, Weiser J. (2017)
Trends in antiretroviral drug use during pregnancy among HIV-infected women on medicaid: 2000-2007. Phiri K, Fischer MA, Mogun H, Williams PL, Palmsten K, Seage GR 3rd, Hernandez-Diaz S. (2014)
Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices. Rimawi BH, Haddad L, Badell ML, Chakraborty R. (2016)
Acceptability and Feasibility of HIV Self-Testing Among Transgender Women in San Francisco: A Mixed Methods Pilot Study. Lippman SA, Moran L, Sevelius J, Castillo LS, Ventura A, Treves-Kagan S, Buchbinder S. (2016)
ARV-based HIV prevention for women – where we are in 2014. Mastro TD, Sista N, Abdool-Karim Q. (2014)
Biomedical Approaches to HIV Prevention in Women. Heumann CL. (2018)
Comprehensive Sexual Health
Biomedical technologies for the prevention of sexually transmitted infections and HIV for adolescent girls and young women. Narasimhan M, Vermund SH, Ogilvie G. (2016)
Beyond the Pap Smear: Gender-responsive HIV Care for Women. Meyer JP, Womack JA, Gibson B. (2016)
Condomless Sex Among Virally Suppressed Women With HIV With Regular HIV-Serodiscordant Sexual Partners in the Era of Treatment as Prevention. Patterson S, Carter A, Nicholson V, Webster K, Ding E, Kestler M, Ogilvie G, de Pokomandy A, Loutfy M, Kaida A. (2017)
Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Koff A, Goldberg C, Ogbuagu O. (2017)
Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. Katz IT, Leister E, Kacanek D, Hughes MD, Bardeguez A, Livingston E, Stek A, Shapiro DE, Tuomala R. (2015)
HIV RNA Suppression during and after Pregnancy among Women in the HIV Outpatient Study, 1996 to 2015. Patel M, Tedaldi E, Armon C, Nesheim S, Lampe M, Palella F Jr, Novak R, Sutton M, Buchacz K; HOPS Investigators. (2018)
Male/Female Condom Use
Assessing and Mapping the Availability of the Female Condom in the Philadelphia Metropolitan Area. Cavanaugh C, Mial K, Tulloch D. (2016)
Consistency of Condom Use During Receptive Anal Intercourse Among Women and Men Who Have Sex With Men: Findings From the Safe in the City Behavioral Study. D’Anna LH, Warner L, Margolis AD, Korosteleva OA, O’Donnell L, Rietmeijer CA, Klausner JD, Malotte CK; Safe in the City Study Group. (2015)
Female Condom Use and Adoption Among Men and Women in a General Low-Income Urban U.S. Population. Weeks MR, Zhan W, Li J, Hilario H, Abbott M, Medina Z. (2015)
Predictors of condom use in women receiving court-mandated drug and alcohol treatment: implications for intervention. DePesa NS, Eldridge GD, Deavers F, Cassisi JE. (2015)
Women’s willingness to experiment with condoms and lubricants: A study of women residing in a high HIV seroprevalence area. Sanders SA, Crosby RA, Milhausen RR, Graham CA, Tirmizi A, Yarber WL, Beauchamps L, Mena L. (2018)
A Qualitative Exploration of Sexual Assault Patients’ Barriers to Accessing and Completing HIV Prophylaxis. Djelaj V, Patterson D, Romero CM. (2017)
Current practice of HIV postexposure prophylaxis treatment for sexual assault patients in an emergency department. Krause KH, Lewis-O’Connor A, Berger A, Votto T, Yawetz S, Pallin DJ, Baden LR. (2014)
HIV post-exposure prophylaxis provided at an urban paediatric emergency department to female adolescents after sexual assault. Merchant RC1, Keshavarz R, Low C. (2004)
PrEP Screening, Eligibility & Guidelines
Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach. Seidman DL, Weber S, Cohan D. (2017)
Optimizing Delivery of HIV Pre-Exposure Prophylaxis for Women in the United States. Aaron E, Blum C, Seidman D, Hoyt MJ, Simone J, Sullivan M, Smith DK. (2018)
2018 8th Women and HIV Abstract 55: Implementation strategies to universally screen, educate about, and offer PrEP to pregnant women at two United States medical centers. Seidman D, Weber S, Scott H, Nordell M, Anderman J, Monaghan K, Timoney M.
2018 8th Women and HIV Abstract 59: Reaching High Risk Women for PrEP: Learning from ARV-based HIV prevention trials. Hoke T, Stankevitz K, Schwartz K, Li Y, Mahaka I, Mullick S.
CROI 2018 Abstract Number 1048: Predictors of PrEP Eligibility Among At-risk Women in the Southern United States. Anar S. Patel, Lakshmi Goparaju, Jessica M. Sales, Cyra Christina Mehta, Oni J. Blackstock, Dominika Seidman, Igho Ofotokun, Mirjam-Colette Kempf, Margaret Fischl, Elizabeth T. Golub, Adaora Adimora, Audrey French, Gina Wingood, Seble Kassaye, Anandi N. Sheth.
PrEP Uptake & Adherence
A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. Bailey JL, Molino ST, Vega AD, Badowski M. (2017)
Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States. van der Straten A, Panther L, Laborde N, Hoesley CJ, Cheng H, Husnik MJ, Horn S, Nel A, Soto-Torres L, Chen BA. (2016)
Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ. (2016)
HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project. Eakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, Saayman E, Moorhouse M, Venter WDF, Rees H; TAPS Demonstration Project Team. (2017)
HIV pre-exposure prophylaxis for women. Sheth AN, Rolle CP, Gandhi M. (2016)
When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Namey E, Agot K, Ahmed K, Odhiambo J, Skhosana J, Guest G, Corneli A. (2016)
2017 7th Women and HIV Abstract 23: A unique population: adherence to PrEP among HIV negative women attempting conception with HIV positive male partners in the US. Aaron E, Leech A, Nkwihoreze H, Drainoni M, Miller E, Coleman Fennell J, Anderson P, Cabral H, Sullivan M.
2018 8th Women and HIV Abstract 51: Dapivirine vaginal ring use: attitudes and experiences across age groups. Malherbe M, Nel A, Smit J, Greener L, Milford C.
2018 8th Women and HIV Abstract 53: Vaginal ring acceptability, adherence and social effect: from phase I to phase III. Malherbe M, Martins J, Isaacs M, Nel.
CROI 2018 Abstract Number 1049: Risk Behavior, Perception, and Reasons for PrEP Among Young African Women in HPTN 082. Connie L. Celum, Sinead Delany-Moretlwe, Sybil Hosek, Bonnie J. Dye, Linda-Gail Bekker, Nyaradzo Mgodi, Wonderful Mabuza, Goodness Zoh Mvuyane, Shorai Mukaka, Deborah J. Donnell, Subash Pathak, Heather Noble, Denni Lennon, Jessica M. Fogel, Peter L. Anderson.
Adherence 2016 Abstract Number 90: Adherence to PrEP among HIV Negative Women Attempting Conception with HIV-Positive Male Partners in the United States. Emily Stinnett Miller, Margaret Sullivan, Mari-Lynn Drainoni , Jenell Coleman, Helen Koenig, Howard Cabral, Peter Anderson, Ashley Leech, Erika Aaron.
Adherence 2016 Abstract Number 104: PrEP Uptake among Cisgender Women at an Urban, Community-Based STI Clinic. Sachin Jain, Cedric Bien, Uri Felsen, Viraj Patel, Oni Blackstock.
CROI 2018 Abstract ID 1014: Increasing PrEP Uptake, Persistent Disparities, in At-risk Patients in a Boston Community Health Center. Kenneth H Mayer, Chris Grasso, Kenneth Levine, Douglas S Krakower, Victoria Powell, Stephen Boswell, Julie L Marcus.
CROI 2018 Abstract ID 1017: Acceptability of Pre-Exposure Prophylaxis (PrEP) Among a Large Cohort of Young Transgender Women in Two U.S. Cities: Findings from LifeSkills Study. Arjee J Restar, Lisa Kuhns, Sari L Reisner, Robert Garofolo, Matthew J Mimiaga.
Adherence 2017 Abstract 181: A Unique Population: Adherence to PrEP among HIV-Negative Women Attempting Conception with HIV-Positive Male Partners in the US. Erika Aaron, Ashley Ann Leech, Mari-Lynn Drainoni, Emily Stinnett Miller, Jenell Coleman, Peter Anderson, Howard Cabral, Margaret Sullivan.
Adherence 2017 Abstract 228: Barriers and Facilitators to Uptake and Adherence to Oral PrEP among Transgender Women in New York City. Christine Rael, Walter Bockting, Caitlin MacCrate, Michelle Martinez, William Mellman, Rebecca Giguere, Pablo Valente, George Greene, Richard D’Aquila, Susan Sherman, Katherine Footer, Alex Carballo-Diéguez.
Adherence 2017 Abstract 384: Health, Intimacy, HIV-Related Anxiety, and Stigma: Perspectives of Women Prescribed HIV Pre-Exposure Prophylaxis at an Urban, Community-Based Sexual Health Clinic. Connie Park, Tonya Taylor, Minia Nataly Rios Gutierrez, Rabea Khedemi, Caryn Weiss, Eileen Dolce, Barry Zingman, Oni Blackstock.
Potential User Knowledge, Attitudes, Beliefs
Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities. Restar AJ, Kuhns L, Reisner SL, Ogunbajo A, Garofalo R, Mimiaga MJ. (2018)
Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city. Peitzmeier SM, Tomko C, Wingo E, Sawyer A, Sherman SG, Glass N, Beyrer C, Decker MR. (2017)
Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City. Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, Valente P, Greene GJ, Sherman S, Footer KHA, D’Aquila RT, Carballo-Diéguez A. (2018)
HIV Pre-Exposure Prophylaxis Stigma as a Multidimensional Barrier to Uptake Among Women Who Attend Planned Parenthood. Calabrese SK, Dovidio JF, Tekeste M, Taggart T, Galvao RW, Safon CB, Willie TC, Caldwell A, Kaplan C, Kershaw TS. (2018)
HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. Rutledge R, Madden L, Ogbuagu O, Meyer JP. (2018)
‘I am not a man’: Trans-specific barriers and facilitators to PrEP acceptability among transgender women. Sevelius JM, Keatley J, Calma N, Arnold E. (2016)
Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. Auerbach JD, Kinsky S, Brown G, Charles V. (2015)
Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. Flash CA, Stone VE, Mitty JA, Mimiaga MJ, Hall KT, Krakower D, Mayer KH. (2014)
Predictors of HIV-related risk perception and PrEP acceptability among young adult female family planning patients. Garfinkel DB, Alexander KA, McDonald-Mosley R, Willie TC, Decker MR. (2017)
Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men. Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. (2017)
Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. Goparaju L, Praschan NC, Warren-Jeanpiere L, Experton LS, Young MA, Kassaye S. (2017)
Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts. Goparaju L, Experton LS, Praschan NC, Warren-Jeanpiere L, Young MA, Kassaye S. (2015)
HIV Pre-Exposure Prophylaxis Stigma as a Multidimensional Barrier to Uptake Among Women Who Attend Planned Parenthood. Calabrese SK , Dovidio JF, Tekeste M, Taggart T, Galvao RW, Safon CB, Willie TC, Caldwell A, Kaplan C, Kershaw TS. (2018)
2017 7th Women and HIV Abstract 20: PrEPing for a PrEP Demonstration Project: Understanding Awareness and Perspectives among Women in Southern California. Blumenthal J, Moore D, Psaros C, Amico R, Ellorin E, Kofron R, Caplan J, Morris S, Landovitz R, Stockman J.
2018 8th HIV & Women Abstract 54: Knowledge and acceptability of HIV pre-exposure prophylaxis (PrEP) in pregnant women. Richards R, Klemmer K, Salmoran F, Hull S, Fernandez S5, Hendrix C, Scott R.
CROI 2018 Abstract Number 1045: Predictors of Willingness to Take PrEP Among Black and Latina Transgender Women. Tonia Poteat, Erin Cooney, Mannat Malik, Thespina Yamanis, Maren Lujan, Andrea L. Wirtz.
Adherence 2017 Abstract Number 269: “We need this!” PrEP awareness and acceptability among women involved in the criminal justice system. Emily F. Dauria, Marina Tolou-Shams, Andrew Levine-Murray, Monique Lipman, Megan Comfort, Katerina Christopoulos.
CROI 2018 Poster ID 1050 HIV Biomedical Prevention Among U.S. Women: Knowledge, Beliefs, and Practices. Sebele Kassaye, Lakshmi Goparaju, Amanda Caste, Lari Warren-Jeanpierre, Anandi Sheth, Adaora Adimora, Margaret Fischl, Elizabeth T Golub, Kathleen Weber, Jennifer Cohen, Kemi Sosanya, Anna Rubtsova, Deborah Konkle-Parker, Tracey Wilson, Chenglong Liu.
CROI 2018 Poster ID 1030: Assessing PrEP Needs Among Heterosexuals and People Who Inject Drugs, Washington, DC. Irene Kuo, Anya Agopian, Jenevieve Opoku, Anthony Rawls, Rudy Patrick, Manya Magnus, Michael Kharfen, Alan Greenberg.
Adherence 2017 Abstract 343: PrEP Stigma and Perceived Disapproval by others may Deter PrEP Uptake among Women. Sarah Calabrese, Trace Kershaw, Abigail Caldwell, Susan Lane, Clair Kaplan, Cara Safon, Rachel Galvao, Mehrit Tekeste.
Adherence 2017 Abstract 355: PrEP Use and Awareness among Transgender Women in South Florida. Cheryl Holder, Hector Perez- Gilbe, Elena Cyrus, Francisco Fajardo, Stephanie Garcia.
Adherence 2017 Abstract 378: PrEP Awareness, Interest, and Use among Women of Color in New York City, 2016. Anisha Gandhi, Emily Appel, Kathleen Scanlin, Julie Myers, Zoe Edelstein.
Conception, Pregnancy & Breastfeeding
Consensus statement: Supporting Safer Conception and Pregnancy For Men And Women Living with and Affected by HIV. Matthews LT, Beyeza-Kashesya J, Cooke I, Davies N, Heffron R, Kaida A, Kinuthia J, Mmeje O, Semprini AE, Weber S. (2018)
Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. Bazzi AR, Leech AA, Biancarelli DL, Sullivan M, Drainoni ML. (2017)
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine. Rough K, Seage GR, Williams PL, Hernandez-Diaz S, Huo Y, Chadwick EG, Currier JS, Hoffman RM, Barr E, Shapiro DE, Patel K; PHACS and the IMPAACT P1025 Study Teams. (2018)
2017 7th HIV & Women Abstract 58: Consensus statement: Supporting safer conception and pregnancy for men and women living with and affected by HIV. Matthews L, Beyeza-Kashesya J, Cooke I, Davies N, Heffron R, Kaida A, Kinuthia J, Mmeje O, Semprini A, Weber S, Safer Conception Consensus Guidelines Working Group.
PrEP Efficacy & Effectiveness
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. Heffron R, McClelland RS, Balkus JE, Celum C, Cohen CR, Mugo N, Bukusi E, Donnell D, Lingappa J, Kiarie J, Fiedler T, Munch M, Fredricks DN, Baeten JM; Partners PrEP Study Team. (2017)
Pre-exposure prophylaxis for HIV prevention in women: current perspectives. Flash CA, Dale SK, Krakower DS. (2017)
CROI 2017 Abstract Number 85: Daily Oral PrEP is Effective Among Women with Abnormal Vaginal Microbiota. Renee Heffron, R. Scott McClelland, Jennifer Balkus, Connie L. Celum, Craig Cohen, Nelly Mugo, Elizabeth A. Bukusi, Deborah J. Donnell, Jared Baeten.
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. Anderson PL, Reirden D, Castillo-Mancilla J. (2018)
Provider Knowledge, Attitudes & Beliefs
Prescribing of Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis by HIV Medical Providers in the United States, 2013-2014. Weiser J, Garg S, Beer L, Skarbinski J. (2017)
Family planning providers’ role in offering PrEP to women. Seidman D, Weber S, Carlson K, Witt J. (2018)
HIV Care Providers’ Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults. Mullins TLK, Zimet G, Lally M, Xu J, Thornton S, Kahn JA. (2017)
United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. (2016)
Adherence 2017 Abstract 406: A Pre-Implementation Assessment: Disconnect between Black Women and their Providers on PrEP. Charlene Flash, Oluwatobi Adegboyega, Syundai Johnson, K. Rivet Amico, Jeffrey Cully, Adaora Adimora, Kenneth Mayer, Thomas Giordano.
Differentiated Approaches (Transgender)
The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. Sevelius JM, Deutsch MB, Grant R. (2016)
Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. (2016)
Adherence 2017 Abstract 279: Transgender Women and Engagement in the Pre-Exposure Prophylaxis Continuum. Thomas Whitfield, Demetria Cain, H. Jonathon Rendina, Sitaji Gurung, Jeffrey Parsons.
US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. Adimora AA, Cole SR, Eron JJ. (2017)